Logo image of ABNX.PA

ABIONYX PHARMA SA (ABNX.PA) Stock Price, Quote, News and Overview

EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR

1.586  -0.06 (-3.76%)

ABNX.PA Quote, Performance and Key Statistics

ABIONYX PHARMA SA

EPA:ABNX (8/8/2025, 7:00:00 PM)

1.586

-0.06 (-3.76%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.05
52 Week Low1.09
Market Cap55.40M
Shares34.93M
Float23.29M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)09-25 2025-09-25
IPO03-30 2015-03-30


ABNX.PA short term performance overview.The bars show the price performance of ABNX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

ABNX.PA long term performance overview.The bars show the price performance of ABNX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 30

The current stock price of ABNX.PA is 1.586 EUR. In the past month the price increased by 32.17%. In the past year, price increased by 20.15%.

ABIONYX PHARMA SA / ABNX Daily stock chart

ABNX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.64 299.58B
AMG.DE AMGEN INC 13.77 132.01B
GIS.DE GILEAD SCIENCES INC 15.46 127.88B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 81.12B
1REGN.MI REGENERON PHARMACEUTICALS 12.43 52.62B
ARGX.BR ARGENX SE 76.6 34.79B
22UA.DE BIONTECH SE-ADR N/A 23.13B
1BIIB.MI BIOGEN INC 8.37 16.66B
IDP.DE BIOGEN INC 7.99 16.10B
1MRNA.MI MODERNA INC N/A 8.76B
0QF.DE MODERNA INC N/A 8.73B
ABVX.PA ABIVAX SA N/A 4.54B

About ABNX.PA

Company Profile

ABNX logo image ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

Company Info

ABIONYX PHARMA SA

Bat. D 33-43 Avenue Georges Pompidou

Balma OCCITANIE FR

Employees: 51

ABNX Company Website

ABNX Investor Relations

Phone: 33562249706

ABIONYX PHARMA SA / ABNX.PA FAQ

What is the stock price of ABIONYX PHARMA SA today?

The current stock price of ABNX.PA is 1.586 EUR. The price decreased by -3.76% in the last trading session.


What is the ticker symbol for ABIONYX PHARMA SA stock?

The exchange symbol of ABIONYX PHARMA SA is ABNX and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ABNX.PA stock listed?

ABNX.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for ABIONYX PHARMA SA stock?

8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 591.36% is expected in the next year compared to the current price of 1.586. Check the ABIONYX PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABIONYX PHARMA SA worth?

ABIONYX PHARMA SA (ABNX.PA) has a market capitalization of 55.40M EUR. This makes ABNX.PA a Micro Cap stock.


How many employees does ABIONYX PHARMA SA have?

ABIONYX PHARMA SA (ABNX.PA) currently has 51 employees.


What are the support and resistance levels for ABIONYX PHARMA SA (ABNX.PA) stock?

ABIONYX PHARMA SA (ABNX.PA) has a support level at 1.23 and a resistance level at 1.74. Check the full technical report for a detailed analysis of ABNX.PA support and resistance levels.


Is ABIONYX PHARMA SA (ABNX.PA) expected to grow?

The Revenue of ABIONYX PHARMA SA (ABNX.PA) is expected to grow by 4.35% in the next year. Check the estimates tab for more information on the ABNX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABIONYX PHARMA SA (ABNX.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABIONYX PHARMA SA (ABNX.PA) stock pay dividends?

ABNX.PA does not pay a dividend.


When does ABIONYX PHARMA SA (ABNX.PA) report earnings?

ABIONYX PHARMA SA (ABNX.PA) will report earnings on 2025-09-25.


What is the Price/Earnings (PE) ratio of ABIONYX PHARMA SA (ABNX.PA)?

ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).


ABNX.PA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 87.28% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ABNX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. While ABNX.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABNX.PA Financial Highlights

Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -7.36% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -32.35%
ROE -58.3%
Debt/Equity 0.25
Chartmill High Growth Momentum
EPS Q2Q%-56.56%
Sales Q2Q%-12.14%
EPS 1Y (TTM)-7.36%
Revenue 1Y (TTM)-1.92%

ABNX.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ABNX.PA. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -37.5% and a revenue growth 4.35% for ABNX.PA


Ownership
Inst Owners4.67%
Ins Owners32.61%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85
Price Target10.97 (591.68%)
EPS Next Y-37.5%
Revenue Next Year4.35%